Page last updated: 2024-11-13

urb937

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

URB937: a peripherally restricted inhibitor of fatty acid amide hydrolase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53394762
CHEMBL ID2402927
SCHEMBL ID528582
MeSH IDM0550918

Synonyms (22)

Synonym
bdbm50437227
chembl2402927 ,
SCHEMBL528582
cyclohexylcarbamic acid 3'-carbamoyl-6-hydroxybiphenyl-3-yl ester
urb937
1357160-72-5
3'-carbamoyl-6-hydroxybiphenyl-3-yl cyclohexylcarbamate
urb-937
AKOS027422596
CS-0065602
HY-116477
NCGC00351474-02
urb 937
3'-(aminocarbonyl)-6-hydroxy[1,1'-biphenyl]-3-yl n-cyclohexylcarbamate
EX-A4088
DTXSID801018151
gtpl11817
A936336
3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate
MS-25529
[3-(3-carbamoylphenyl)-4-hydroxyphenyl] n-cyclohexylcarbamate
AC-36524

Research Excerpts

Overview

URB937 is a peripherally restricted inhibitor of the anandamide-deactivating enzyme fatty-acid amide hydrolase (FAAH)

ExcerptReferenceRelevance
"URB937 is a peripherally restricted inhibitor of the anandamide-deactivating enzyme fatty-acid amide hydrolase (FAAH). "( Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier.
Bertorelli, R; Guijarro, A; Moreno-Sanz, G; Oluyemi, O; Piomelli, D; Reggiani, A; Sasso, O, 2012
)
2.06

Treatment

ExcerptReferenceRelevance
"Treatment with URB937 decreased leukocyte migration and inflammatory cytokines in bronchoalveolar lavage fluid and plasma at day 30."( The Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates Radiation-Induced Lung Injury in a Mouse Model.
Chen, G; Deng, L; Lan, J; Li, R; Lu, Y; Tang, F; Tong, R; Xu, H; Xue, J; Zhou, L, 2017
)
1.06

Pharmacokinetics

The favourable pharmacokinetic and pharmacodynamic properties of URB937, along with its tolerability, encourage further development studies on this compound.

ExcerptReferenceRelevance
" We examined, in rats, (1) the pharmacokinetic profile of oral URB937; (2) the compound's ability to elevate levels of the representative FAAH substrate, oleoylethanolamide (OEA); and (3) the compound's tolerability after oral administration."( Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats.
Ahmed, F; Choobchian, P; Duranti, A; Merrill, CB; Mor, M; Piomelli, D; Rivara, S; Tarzia, G; Tontini, A; Vozella, V; Zibardi, C, 2019
)
1
" The favourable pharmacokinetic and pharmacodynamic properties of URB937, along with its tolerability, encourage further development studies on this compound."( Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats.
Ahmed, F; Choobchian, P; Duranti, A; Merrill, CB; Mor, M; Piomelli, D; Rivara, S; Tarzia, G; Tontini, A; Vozella, V; Zibardi, C, 2019
)
1

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.00200.00030.71237.0700AID759738
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.00200.00051.33138.0000AID759738
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1363878Inhibition of FAAH in Wistar rat brain membranes using [3H]-anandamide as substrate preincubated for 10 mins followed by substrate addition measured after 4 mins by liquid scintillation counting method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID759729In vivo inhibition of FAAH in sc dosed Swiss Webster mouse brain using [3H]-ethanolamine as substrate after 1 hr by liquid scintillation counting analysis2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
AID759724Selectivity ratio of ED50 for inhibition of FAAH in ip dosed Swiss Webster mouse brain to ED50 for inhibition of FAAH in ip dosed Swiss Webster mouse peripheral tissue2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
AID759733In vivo inhibition of FAAH in ip dosed Swiss Webster mouse brain using [3H]-ethanolamine as substrate after 1 hr by liquid scintillation counting analysis2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
AID759738Inhibition of Wistar rat brain FAAH using [3H]-ethanolamine as substrate preincubated for 20 mins followed by substrate addition by liquid scintillation counting analysis2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
AID759732In vivo inhibition of FAAH in Swiss Webster mouse brain using [3H]-ethanolamine as substrate at 25 mg/kg, sc after 1 hr by liquid scintillation counting analysis in presence of Abcg2 inhibitor Ko-1432013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
AID759727In vivo inhibition of FAAH in ip dosed Swiss Webster mouse liver2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
AID759735In vivo inhibition of FAAH in Swiss Webster mouse brain using [3H]-ethanolamine as substrate at 1 mg/kg, ip after 1 hr by liquid scintillation counting analysis relative to control2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
AID759737In vivo inhibition of FAAH in Swiss Webster mouse liver using [3H]-ethanolamine as substrate at 1 mg/kg, ip after 1 hr by liquid scintillation counting analysis relative to control2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
AID759726Selectivity ratio of ED50 for inhibition of FAAH in ip dosed Swiss Webster mouse brain to ED50 for inhibition of FAAH in ip dosed Swiss Webster mouse liver2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
AID759725In vivo inhibition of FAAH in ip dosed Swiss Webster mouse peripheral tissue2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's19 (82.61)24.3611
2020's4 (17.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.73 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index6.32 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]